BACKGROUND: Generic health preference measures that capture quality of life improvements in depression are important for economic analysis of new technologies. AIM: To compare two widely used preference measures, the EQ-5D and SF-6D, in terms of their dimensions and health utility values. METHOD:EQ-5D and SF-6D data collected from 114 patients with depression, who participated in a cluster, randomised controlled trial to evaluate a collaborative care intervention in UK, primary care practices. Utilities were examined across the whole sample and by level of depression severity using the PHQ-9. RESULTS:Depression was associated with disutility at baseline. At 3 month follow-up mean utility increased 0.147 for EQ-5D and 0.082 for SF-6D. Health gains were observed in patients in remission from depression and those with the mildest level of depression severity. CONCLUSIONS: Both generic preference measures were sensitive to health gains in depression within a relatively short follow-up period; larger health gain was observed for the EQ-5D.
RCT Entities:
BACKGROUND: Generic health preference measures that capture quality of life improvements in depression are important for economic analysis of new technologies. AIM: To compare two widely used preference measures, the EQ-5D and SF-6D, in terms of their dimensions and health utility values. METHOD: EQ-5D and SF-6D data collected from 114 patients with depression, who participated in a cluster, randomised controlled trial to evaluate a collaborative care intervention in UK, primary care practices. Utilities were examined across the whole sample and by level of depression severity using the PHQ-9. RESULTS:Depression was associated with disutility at baseline. At 3 month follow-up mean utility increased 0.147 for EQ-5D and 0.082 for SF-6D. Health gains were observed in patients in remission from depression and those with the mildest level of depression severity. CONCLUSIONS: Both generic preference measures were sensitive to health gains in depression within a relatively short follow-up period; larger health gain was observed for the EQ-5D.
Authors: Patrik Sobocki; Mattias Ekman; Hans Agren; Ingvar Krakau; Bo Runeson; Björn Mårtensson; Bengt Jönsson Journal: Value Health Date: 2007 Mar-Apr Impact factor: 5.725
Authors: Nancy A Pike; Lorraine S Evangelista; Lynn V Doering; Jo-Ann Eastwood; Alan B Lewis; John S Child Journal: J Cardiovasc Nurs Date: 2012 Nov-Dec Impact factor: 2.083
Authors: Katherine E Watkins; Alison E Cuellar; Kimberly A Hepner; Sarah B Hunter; Susan M Paddock; Brett A Ewing; Erin de la Cruz Journal: J Subst Abuse Treat Date: 2013-10-02
Authors: Nicholas Turner; John Campbell; Tim J Peters; Nicola Wiles; Sandra Hollinghurst Journal: Health Qual Life Outcomes Date: 2013-05-09 Impact factor: 3.186